Want to see TSE:RX full AI Analyst Report?
RX Stock Chart & Stats
C$15.70
-C$0.09(-0.61%)
At close: 4:00 PM EDT
C$15.70
-C$0.09(-0.61%)
Day’s Range― - ―
52-Week RangeC$10.65 - C$17.50
Previous CloseN/A
Volume2.74K
Average Volume (3M)7.85K
Market Cap
C$191.80M
Enterprise ValueC$162.82M
Total Cash (Recent Filing)C$8.94M
Total Debt (Recent Filing)C$3.14M
Price to Earnings (P/E)19.4
Beta0.84
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.26%
Share Statistics
EPS (TTM)0.88
Shares Outstanding11,308,835
10 Day Avg. Volume5,657
30 Day Avg. Volume7,849
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)3.46
Price to Sales (P/S)3.33
P/FCF Ratio14.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$18.00Price Target Upside14.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.89
Revenue Forecast (FY)C$69.00M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth indicates expanding demand for Biosyent’s marketed healthcare portfolio and supports continued operating leverage. A multi-year upward trend also provides a stronger foundation for reinvestment, product expansion, and durable earnings growth over the next several quarters.
High ProfitabilityHigh gross, operating, and net margins show that Biosyent’s commercialization model is generating substantial value from product sales. This profitability can support sales investment, licensing activity, and resilience against moderate cost or product-mix pressure.
Conservative Balance SheetVery low leverage gives Biosyent meaningful financial flexibility and reduces the burden of interest or refinancing obligations. Growing equity and expanding assets strengthen its capacity to support product commercialization and pursue opportunities without relying heavily on debt.
Bears Say
Margin CompressionAlthough profitability remains strong, declining gross and net margins suggest that product mix or operating costs may be becoming less favorable as the business scales. If sustained, this could limit earnings growth even while revenue continues to increase.
Variable Cash ConversionRecent cash conversion is less consistent than the company’s earnings performance, with lower operating cash flow relative to net income and a decline in free cash flow. Persistent working-capital or reinvestment effects could reduce internally funded flexibility.
Higher DebtThe increase in debt warrants monitoring because additional borrowing could gradually reduce the balance-sheet conservatism that currently supports Biosyent’s financial flexibility. Debt remains modest, but growth in leverage should stay aligned with business expansion.
RX FAQ
What was Biosyent Inc’s price range in the past 12 months?
Biosyent Inc lowest stock price was C$10.65 and its highest was C$17.50 in the past 12 months.
What is Biosyent Inc’s market cap?
Biosyent Inc’s market cap is C$191.80M.
When is Biosyent Inc’s upcoming earnings report date?
Biosyent Inc’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were Biosyent Inc’s earnings last quarter?
Biosyent Inc released its earnings results on Aug 20, 2026. The company reported C$0.25 earnings per share for the quarter.
Is Biosyent Inc overvalued?
According to Wall Street analysts Biosyent Inc’s price is currently Undervalued.
Does Biosyent Inc pay dividends?
Biosyent Inc pays a Quarterly dividend of C$0.055 which represents an annual dividend yield of 1.26%. See more information on Biosyent Inc dividends here
What is Biosyent Inc’s EPS estimate?
Biosyent Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biosyent Inc have?
Biosyent Inc has 11,308,835 shares outstanding.
What happened to Biosyent Inc’s price movement after its last earnings report?
Biosyent Inc reported an EPS of C$0.25 in its last earnings report. Following the earnings report the stock price went up 4.217%.
Which hedge fund is a major shareholder of Biosyent Inc?
Currently, no hedge funds are holding shares in TSE:RX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biosyent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$18.00 (14.65% Upside)
C$18.00 (14.65% Upside)
Insider Transactions
Sold Shares
Worth C$272.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.34%
12-Months-Change
Fundamentals
Return on Equity
22.92%
Trailing 12-Months
Asset Growth
39.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Biosyent Inc
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. BioSyent Inc. was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. The company was incorporated in 2006 and is headquartered in Mississauga, Canada.
RX Stock 12 Month Forecast
Average Price Target
C$18.00
▲(14.65% Upside)
Technical Analysis
Aequus Pharmaceuticals
―
Willow Biosciences Inc
―
Medexus Pharmaceuticals Inc
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―